Announcements Trials
Browse Landscape

Phase

Phase 4 3Phase 1 1

Status

Completed 4

Sponsor Class

OTHER 14INDUSTRY 4OTHER_GOV 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Tumor-Agnostic 1Thoracic 1Lymphoid 1Endocrine 1Breast 1

Conditions

Barrett Esophagus 3Zollinger-Ellison Syndrome 1Stomach Ulcer 1Esophagitis, Peptic 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Esomeprazole × Gastrointestinal × Clear all
NCT00942175 2012-02-03

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

Takeda

Phase 1 Completed
160 enrolled 16 charts
Gastrointestinal

Esophagitis, Peptic, Stomach Ulcer, Zollinger-Ellison Syndrome

NCT00637559 2011-01-25

Barrett's Esophagus - 315 - 3 Way Cross-Over

AstraZeneca

Phase 4 Completed
50 enrolled
Gastrointestinal

Barrett Esophagus

NCT00637988 2011-01-21

Barrett's Esophagus - 315 - 3 Way Cross Over

AstraZeneca

Phase 4 Completed
32 enrolled
Gastrointestinal

Barrett Esophagus

NCT00352261 2009-03-26

An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

AstraZeneca

Phase 4 Completed
80 enrolled
Gastrointestinal

Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡